Biotech | September 12, 2025
iRegene Therapeutics secures series B+ financing
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The payment is in accordance with the agreed contractual terms
The company has received approval from DCGI to begin patient enrolment and dosing in the country
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Subscribe To Our Newsletter & Stay Updated
